Kyung Dong Pharmaceutical Co. Ltd
Kyung Dong Pharmaceutical Co., Ltd. produces and sells specialized and general medicines in South Korea. It offers prescription medicines for liver therapy, antispasmodic, antidiabetic, antiviral, corticosteroid, androgen alopecia, muscle relaxant, antimigraine, vitamin, antifungal, endocrinal, urology, antibacterial, cardiovascular, pain/inflammation, smoking cessation aid, gastrointestinal, ant… Read more
Kyung Dong Pharmaceutical Co. Ltd (011040) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.036x
Based on the latest financial reports, Kyung Dong Pharmaceutical Co. Ltd (011040) has a cash flow conversion efficiency ratio of 0.036x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩7.76 Billion) by net assets (₩217.26 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kyung Dong Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Kyung Dong Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Kyung Dong Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kyung Dong Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tembo Global Industries Limited
NSE:TEMBO
|
0.005x |
|
Saksiam Leasing Public Company Limited
BK:SAK
|
0.184x |
|
Peter Warren Automotive Holdings Ltd
AU:PWR
|
0.106x |
|
Silk Logistics Holdings Ltd
AU:SLH
|
0.381x |
|
T.K.S. Technologies Public Company Limited
BK:TKS
|
0.027x |
|
ImageneBio, Inc.
NASDAQ:IMA
|
-0.191x |
|
Cameo Communications Inc
TW:6142
|
-0.032x |
|
ReaLy Development & Construction
TWO:2596
|
-0.097x |
Annual Cash Flow Conversion Efficiency for Kyung Dong Pharmaceutical Co. Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Kyung Dong Pharmaceutical Co. Ltd from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩220.06 Billion | ₩-8.07 Billion | -0.037x | -26148.62% |
| 2023-12-31 | ₩228.48 Billion | ₩-31.94 Million | 0.000x | +96.66% |
| 2022-12-31 | ₩257.20 Billion | ₩-1.07 Billion | -0.004x | -108.74% |
| 2021-12-31 | ₩259.82 Billion | ₩12.42 Billion | 0.048x | -26.76% |
| 2020-12-31 | ₩262.19 Billion | ₩17.12 Billion | 0.065x | +632.25% |
| 2019-12-31 | ₩226.71 Billion | ₩-2.78 Billion | -0.012x | -107.81% |
| 2018-12-31 | ₩211.72 Billion | ₩33.27 Billion | 0.157x | +134.79% |
| 2017-12-31 | ₩220.95 Billion | ₩14.79 Billion | 0.067x | -45.18% |
| 2016-12-31 | ₩209.93 Billion | ₩25.63 Billion | 0.122x | +37.17% |
| 2015-12-31 | ₩205.14 Billion | ₩18.26 Billion | 0.089x | -25.43% |
| 2014-12-31 | ₩190.43 Billion | ₩22.73 Billion | 0.119x | +22.85% |
| 2013-12-31 | ₩169.03 Billion | ₩16.42 Billion | 0.097x | -25.16% |
| 2012-12-31 | ₩153.76 Billion | ₩19.96 Billion | 0.130x | -25.02% |
| 2011-12-31 | ₩150.62 Billion | ₩26.08 Billion | 0.173x | -- |